Cargando…
The latency-reversing agent HODHBt synergizes with IL-15 to enhance cytotoxic function of HIV-specific T cells
IL-15 is under clinical investigation toward the goal of curing HIV infection because of its abilities to reverse HIV latency and enhance immune effector function. However, increased potency through combination with other agents may be needed. 3-Hydroxy-1,2,3-benzotriazin-4(3H)-one (HODHBt) enhances...
Autores principales: | Copertino, Dennis C., Holmberg, Carissa S., Weiler, Jared, Ward, Adam R., Howard, J. Natalie, Levinger, Callie, Pang, Alina P.S., Corley, Michael J., Dündar, Friederike, Zumbo, Paul, Betel, Doron, Gandhi, Rajesh T., McMahon, Deborah K., Bosch, Ronald J., Linden, Noemi, Macatangay, Bernard J., Cyktor, Joshua C., Eron, Joseph J., Mellors, John W., Kovacs, Colin, Benko, Erika, Bosque, Alberto, Jones, R. Brad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561764/ https://www.ncbi.nlm.nih.gov/pubmed/37581929 http://dx.doi.org/10.1172/jci.insight.169028 |
Ejemplares similares
-
The HIV Latency Reversal Agent HODHBt Enhances NK Cell Effector and Memory-Like Functions by Increasing Interleukin-15-Mediated STAT Activation
por: Macedo, Amanda B., et al.
Publicado: (2022) -
108. Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy
por: Gandhi, Rajesh, et al.
Publicado: (2020) -
TCF12 Deficiency Impairs the Proliferation of Glioblastoma Tumor Cells and Improves Survival
por: Pang, Yunong, et al.
Publicado: (2023) -
Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation
por: Gandhi, Rajesh T., et al.
Publicado: (2017) -
Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART
por: Riddler, Sharon A, et al.
Publicado: (2018)